Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Envoy Medical Inc. (COCH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: COCH (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -75.34% | Avg. Invested days 56 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 27.89M USD | Price to earnings Ratio - | 1Y Target Price 6.5 |
Price to earnings Ratio - | 1Y Target Price 6.5 | ||
Volume (30-day avg) 18636 | Beta 2.36 | 52 Weeks Range 1.21 - 7.20 | Updated Date 04/2/2025 |
52 Weeks Range 1.21 - 7.20 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.28 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -10771.43% |
Management Effectiveness
Return on Assets (TTM) -125.51% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 39079957 | Price to Sales(TTM) 123.98 |
Enterprise Value 39079957 | Price to Sales(TTM) 123.98 | ||
Enterprise Value to Revenue 140.58 | Enterprise Value to EBITDA -1.35 | Shares Outstanding 21293900 | Shares Floating 10717479 |
Shares Outstanding 21293900 | Shares Floating 10717479 | ||
Percent Insiders 50.22 | Percent Institutions 9.56 |
Analyst Ratings
Rating 5 | Target Price 6.55 | Buy - | Strong Buy 4 |
Buy - | Strong Buy 4 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Envoy Medical Inc.
Company Overview
History and Background
Envoy Medical Inc. is a hearing health company focused on developing innovative, fully implanted medical devices to treat hearing loss. The company's history involves significant milestones in creating and refining fully implantable hearing solutions.
Core Business Areas
- Hearing Loss Solutions: Develops and manufactures fully implanted hearing devices designed to improve hearing for individuals with sensorineural hearing loss.
Leadership and Structure
Details regarding the specific leadership team and organizational structure of Envoy Medical Inc. would require accessing up-to-date company filings or press releases.
Top Products and Market Share
Key Offerings
- Esteemu00ae Fully Implanted Hearing Device: Envoy Medical's Esteemu00ae is a fully implanted hearing device designed to restore natural hearing. Specific market share data is difficult to obtain, but it competes with traditional hearing aids and cochlear implants from companies like Cochlear (CI) and Sonova (SONVY). It serves a niche market within the broader hearing loss treatment landscape.
Market Dynamics
Industry Overview
The hearing aid market is experiencing growth due to the aging global population and increasing awareness of hearing loss. Technological advancements, like fully implanted devices, are driving innovation.
Positioning
Envoy Medical is positioned as an innovator with its fully implanted device, targeting a segment seeking a discreet and potentially higher-performing solution compared to traditional hearing aids.
Total Addressable Market (TAM)
The global hearing aid market is estimated to be in the tens of billions of dollars. Envoy Medical is targeting a portion of this TAM with its fully implanted solution, representing a premium and niche segment. Actual TAM applicable to Envoy Medical is lower because it does not address conductive or mixed hearing loss. TAM for sensorineural hearing loss is still substantial.
Upturn SWOT Analysis
Strengths
- Innovative, fully implanted technology
- Potential for superior hearing performance
- Discreet solution appealing to some users
Weaknesses
- High cost compared to traditional hearing aids
- Surgical procedure required for implantation
- Limited market penetration compared to larger competitors
Opportunities
- Expanding market for hearing loss solutions
- Technological advancements in hearing implants
- Partnerships with audiologists and ENT specialists
Threats
- Competition from established hearing aid manufacturers
- Regulatory hurdles for new medical devices
- Reimbursement challenges from insurance providers
Competitors and Market Share
Key Competitors
- CI
- SONVY
- GNNDF
- OTCMKTS:SIFIX
Competitive Landscape
Envoy Medical's advantage lies in its fully implanted technology, offering a unique value proposition. However, it faces challenges related to cost, surgical requirements, and competition from established players.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends require access to the company's financial reports over several years.
Future Projections: Future growth projections would typically be based on analyst estimates, which may not be readily available for a company like Envoy Medical.
Recent Initiatives: Recent initiatives would involve updates on product development, clinical trials, and market expansion efforts. Requires active monitoring of company press releases.
Summary
Envoy Medical is a niche player with a fully implanted hearing solution, offering a unique discreetness that is not available with traditional hearing aids. Its growth depends on its ability to expand market penetration and address cost challenges, while effectively competing with larger competitors, and navigating regulatory and reimbursement landscapes. They can achieve greater growth by focusing on continuous improvement in their technology. It's a relatively risky, high-reward potential investment.
Similar Companies
CI
Cigna Corp
CI
Cigna Corp
Sources and Disclaimers
Data Sources:
- Company website
- Industry reports
- Analyst reports (where available)
- General knowledge of the hearing aid market
Disclaimers:
This analysis is based on publicly available information and general market knowledge. Financial data and market share information are estimates. This is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Envoy Medical Inc.
Exchange NASDAQ | Headquaters White Bear Lake, MN, United States | ||
IPO Launch date 2021-04-29 | CEO & Director Mr. Brent T. Lucas Esq. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 34 | Website https://www.envoymedical.com |
Full time employees 34 | Website https://www.envoymedical.com | ||
Envoy Medical, Inc., a hearing health company, focuses on providing medical technologies across the hearing loss spectrum. The company's medical technologies are designed to shift the paradigm within the hearing industry and bring providers and patients the hearing devices desire. Its products include personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc. in September 2023. Envoy Medical, Inc. was founded in 1995 and is headquartered in White Bear Lake, Minnesota.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.